The current prognosis group from American Joint Committee on Cancer (AJCC) guidelines shows some contradictory results. We suggest that pathologic Gleason score should be weighed more than prostatespecific antigen level in predicting patient prognosis. Our new stratification system showed better prognostic ability than the current system. Introduction: The American Joint Committee on Cancer (AJCC) tumor, node, metastasis classification system (TNM) staging manual has been updated and provides more specified stage grouping for prostate cancer (PCa). We aimed to validate the updated AJCC stage groups for PCa using a radical prostatectomy (RP) cohort. Patients and Methods: We analyzed the data of 3032 patients previously treated with RP for localized PCa. We stratified patients into stage groups according to the 8th edition of the AJCC manual and compared biochemical recurrence (BCR)-free survival using Kaplan-Meier analyses. Results: There were 217 patients in stage group I, 33 in IIA, 1101 in IIB, 535 in IIC, 129 in IIIA, 781 in IIIB, and 236 in IIIC. There were no significant differences in BCR-free survival between stage groups IIC and IIIA (P ¼ .875). Subsequently, the loweGleason score (GS) IIIA subgroup (GS 3 þ 4, P ¼ .025) showed superior BCR-free survival than the IIC group, and the high-GS IIIA subgroups (GS 4 þ 3, P ¼ .004) showed a poorer BCRfree survival than the IIC group. Furthermore, there were no significant differences between groups I and IIA (P ¼ 330) and between groups IIA and IIB (P ¼ .942). Our new staging system provided a better ability to discriminate the prognosis of each group. However, our study has several limitations, such as retrospective design, relatively short follow-up period, and need for further validation. Conclusion: The current AJCC prognostic groups show some contradictory results, particularly concerning prognosis of the IIC and IIIA groups. We suggest that GS be given more weight than serum prostate-specific antigen level in stage group stratification.
Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of death due to cancer. 1, 2 However, PCa comprises various subsets of tumors that exhibit different clinical behavior. 3, 4 Some PCa types show aggressive behavior, metastasize to other organs, and are life-threatening. 3 However, most early-stage low-grade PCas tend to develop slowly, showing an indolent clinical course. 4 Radical treatment, including radical prostatectomy (RP) and radiotherapy, inevitably results in a reduction in quality of life; therefore, a new surveillance strategy has been adopted by contemporary clinicians over the last decade. 5, 6 An accurate prediction of the prognosis of PCa patients has become more important clinically to guide appropriate treatment choices. The best-known traditional prognostic factors for PCa are Gleason score (GS), serum prostate-specific antigen (PSA) level, and tumor stage. 7, 8 Moreover, novel molecular prognostic biomarkers have now been approved by the US Food and Drug Administration and are commercially available. 9 In December 2016, the American Joint Committee on Cancer (AJCC) published the 8th edition of the clinical manual for PCa, which included revisions to the PCa stages to provide more accurate prognostic information. 10 Briefly, there have been notable changes to the 8th edition, including a new definition of pT2 disease without the previous concepts of laterality or disease extent, introduction of the International Society of Urological Pathology Consensus Conference (ISUP) grade groupings, and inclusion of T4 disease into the IIIB group. 11 Additionally, the 8th edition of the AJCC guideline has introduced a new IIC stage group, between the IIB and IIIA groups, which has been defined as comprising T stage 1-2, PSA level < 20 ng/dL, and grade group 3 or 4 with no clinical findings indicating lymph node or distant metastasis. Patients with an elevated PSA of > 20 ng/dL are now classified as having IIIA disease, regardless of GS, even though the disease is localized. However, changes require validation with clinical data. Therefore, we aimed to validate the predictive ability of the new stage group system from the 8th edition of the AJCC guidelines by analyzing our PCa cohort database in terms of biochemical recurrence (BCR) after RP in patients with localized PCa.
Patients and Methods
After obtaining approval from our institutional review boards, we reviewed the data of 3097 PCa patients who could be classified within the recent definition of AJCC prognosis groups I to IIIC, and who had been treated using RP for localized PCa from May 2006 to December 2015. After excluding 65 patients (preoperative radiotherapy, n ¼ 8; preoperative hormone therapy, n ¼ 15; and incomplete information, n ¼ 42), we finally included 3032 patients in the study. RP was performed using an open retropubic, robotassisted, or laparoscopic approach by 4 surgeons who had more than 10 years of RP experience.
Ethical Standards
The present study does not contain clinical studies or patient data and was permitted by institutional review board (approval B-1802-448-111) of Seoul National University Bundang Hospital, Seongnam, Korea.
The disease of all patients was subdivided into the stage groups proposed in the AJCC 8th edition guidelines (Table 1) . 12 All pathologic grading and staging were performed by a single pathologist using the modified definitions of the 2005 ISUP consensus conference and the 6th edition of the AJCC guidelines. 13, 14 Postoperative follow-up was routinely performed at 3-to 6-month intervals during the first 2 years and yearly thereafter. BCR was defined when the patients had a recorded PSA level of > 0.2 ng/mL in 2 consecutive measurements. Chi-square tests and independent t tests were performed to compare the differences in clinical variables between the groups. Kaplan-Meier analyses with the log-rank test were utilized to compare the BCR-free survival between the prognosis groups. The area under the receiver operating characteristic (ROC) curve was calculated by the Delong method. Statistical analyses were performed by SPSS 19.0 (IBM, Armonk, NY) and MedCalc 18.0 (Mariakerke, Belgium). All P values are presented as 2-sided values, and P < .05 was considered to have statistical significance.
Results
The clinical characteristics and pathologic outcomes for all 3032 patients are summarized in Table 2 . There were 544 patients (17.9%) with BCR after a median of 11 (range, 3.0-27.8) months, and 417 patients (3.8%) were lost to follow-up. When we performed the Kaplan-Meier analysis of the biopsy GS on the postoperative BCR in entire subjects, we observed that our biopsy GS was well discriminating the postoperative BCR-free survival according to the increase of biopsy GS (P < .001, Figure 1A ). We identified 217 patients in group I, 33 in group IIA, 1101 in group IIB, 535 in group IIC, 129 in group IIIA, 781 in group IIIB, and 236 in group IIIC. There were no significant differences in patients' age, body mass index, and history of diabetes mellitus or hypertension between each group (all P > .05). Prostate Cancer Stage Groups
When we compared the BCR-free survival between the stage groups ( Figure 1B ), there were significant differences between groups IIB and IIC, between groups IIIA and IIIB, and between groups IIIB and IIIC (all P < .001). However, there were no significant differences between groups I and IIA (P ¼ .330), IIA and IIB (P ¼ .942), and IIC and IIIA (P ¼ .843), respectively. The area under the ROC curve of 8th AJCC stage group was calculated as 0.774 (95% confidence interval (CI), 0.759-0.788) in predicting the postoperative BCR at 23 months after surgery. To evaluate why the IIC group did not show favorable outcomes compared to the IIIA group, we subsequently divided the IIIA group into subgroups according to GS. As shown in Figure 2 , the IIIA low-GS groups ( 3 þ 4) showed significantly more favorable BCR-free survival than the IIC group (P ¼ .028), and the IIIA high-GS group ( 4 þ 3) showed significantly poorer survival outcomes than the IIC group (P ¼ .004). However, no significant difference between the IIC and IIIA GS (4 þ 3) groups was noted (P ¼ .115).
From our results, we considered that the classification of stage groups should be performed according to prior consideration of the GS rather than the PSA level. Therefore, we divided our patients according to our revised version of the prognostic groups (Table 1) . Groups I and IIA were combined into a new group I. Group IIC was merged into a new group IIIA, and the IIIA low-GS subgroup was included in new group II, which was combined with the original IIB group. The subsequent Kaplan-Meier analysis demonstrated that our new simplified prognosis groups showed good discrimination for prognosis (P < .001) in terms of BCR-free survival after surgery (Figure 3) . Furthermore, the area under the ROC curve of our new stage group, at 0.807 (95% CI, 0.793-0.820) was revealed to be significantly higher than the 8th AJCC stage group (P < .001) at the time point of 23 months (Figure 4 ).
Discussion
In this study, we sought to validate the prognostic performance of the AJCC 8th stage group using the data of 3032 patients with localized PCa surgically treated with RP. It is noteworthy that the IIC group in the 8th edition of AJCC guidelines did not show any significant difference compared to the IIIA group in regard to BCRfree survival. Moreover, the IIIA low-GS subgroup did show significantly superior BCR-free survival than the IIC group, although patients numbers were relatively small. We believe that those patients with high PSA and low GS should be considered to have a more favorable prognosis than the other IIIA high-GS patients. Subsequently, using our results, we revised the AJCC stage group, giving more weight to the GS than the PSA level. Our new model is relatively simple and showed significant improved ability in discriminating the prognosis of each group in terms of postoperative BCR-free survival between the IIB and IIIA groups. Although the PSA level is one of most important prognostic biomarkers in PCa, we consider that the GS should be given more weight in determining the stage groups.
We are not the first to test the validity of the 8th edition of AJCC stage group. Xiao et al 15 aimed to validate the 8th edition of the AJCC stage group system through analyzing the Surveillance, Epidemiology and End Results database that included 138,176 patients. 15 They concluded that there were no significant differences in cancer-specific survival between T2a/T2b and T2c (P ¼ .323). They showed that patients with T2 disease with a high PSA ( 20 ng/dL) showed better cancer-specific survival than those in the IIIB group, which supports the current system of the 8th edition stage groups in relation to revision of the T2 disease definition. Bhindi et al 16 performed a similar validation of the 8th edition of the AJCC staging manual. They analyzed a large database involving 13,839 RP patients treated at the Mayo Clinic and showed that patients with a high PSA level (> 20 ng/dL) in the 7th edition stage group II had significantly worse survival outcomes than stage group II patients with a low PSA level (< 20 ng/dL). However, patients with a high PSA level (> 20 ng/dL) in the 7th edition stage group II showed significantly better survival outcomes than the patients in the 7th edition stage III group. They concluded that their findings supported the addition of a new IIIA group in the 8th edition stage group. Although the authors did not focus on differences in survival outcomes between groups IIC and IIIA, we observed the same nonsignificant difference between groups IIC and IIIA in the 8th edition stage group in metastasis-free, cancer-specific, and overall survival. A study by Abdel-Rahman also demonstrated similar analyzed data of 72,999 patients from the Surveillance, Epidemiology and End Results database and showed that there were significant differences in cancer-specific survival between groups IIB and IIC (hazard ratio ¼ 0.384, P ¼ .026), but no significant difference between groups IIC and IIIA (hazard ratio 0.772, P ¼ .38), which concurs with our results. These consistent findings from previous studies showing nonsignificant differences between IIC and IIIA support our study findings. On the other hand, we could not find any relevant description in these studies concerning whether repeat grading or central review for GS in patients who had surgery before the 2005 ISUP GS modification had been undertaken. Because there had been significant changes to the 2005 ISUP modified GS grading system, bias could have been introduced if there was no uniform application of GS grading. In the present study, to avoid possible bias, we only included patients who had histologic GS grading according to the 2005 ISUP modified grading system. The GS has been known to be the single most powerful predictor for the PCa prognosis. 18 However, there has been considerable heterogeneity in GS grouping in contemporary studies. The Prostate Cancer Outcomes study stratified patients according to GS 2-4, 5-7, and 8-10, 19 whereas the Scandinavian Prostate Cancer Group study stratified patients as GS 2-6, 7, and 8-10. 20 The D'Amico classification system comprises a 3-tiered GS grouping system (2-6, 7, and 8-10). 21 Epstein et al 18 suggested a new 5-tiered grade grouping, as follows: grade group 1 (GS 3þ3), grade group 2 (GS 3 þ 4), grade group 3 (GS 4 þ 3), Grade group 4 (GS 8), and grade group 5 (GS 9-10). The World Health Organization and the International Society for Urologic Pathology formally adopted this new 5-tiered grade group system, 22 and the 8th edition of the AJCC manual also adopted this new grade group system into the stage group system.
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In the 8th edition of the AJCC manual, the stage group stratifies patients into 9 groups according to T stage, PSA level, and grade group. The current grouping system prioritizes the PSA level, not the GS. For example, patients with GS 6, T2 stage, and PSA level 21 ng/dL are classified as having IIIA disease. On the other hand, patients with a low PSA and a high GS 8 are classified as having IIC disease within the current AJCC stage group. However, patients with a low GS and a high PSA showed significantly superior BCR-free outcomes than those with a low PSA and a high GS in the present study, even though those patients with a low GS and a high PSA level were very small in number (2.3%, 70/3032 patients). Moreover, similar nonsignificant differences were also observed between the stage groups I and IIA, as well as between IIA and IIB.
The current AJCC manual has 2 different groups for patients with a GS of 6 and a low PSA ( 20 ng/dL). However, we could not find any significant difference between groups I and IIA (P ¼ .330) or between groups IIB and IIA (P ¼ .942) in terms of BCRfree survival postoperatively. Therefore, it is reasonable to question the reliability of the current AJCC stage grouping. A further issue regarding the current AJCC grade grouping is that it is too complex to use. It comprises 7 different groups for localized PCa patients only, and 2 different groups for patients with positive nodes and/or metastasis. The new grade groups proposed by Epstein et al 18 aimed to simplify the GS system, and the current AJCC stage group system also needs to be revised to a more simplified version. We believe that further efforts should be undertaken to enhance the stage group system of the current AJCC manual, including further validation of the aforementioned issues. Our study has several limitations. First, it is limited by its retrospective design. Second, the present study only analyzed RP patients and did not include other treatments, such as radiotherapy or focal therapies. More importantly, we could only analyze BCRfree survival without consideration of other survival outcomes, such as cancer-specific or overall survival. Third, our study comprised a Korean population only; therefore, further validations are required using various end points in other ethnic groups that have been treated using other treatment modalities, including RP. Fourth, our study is limited by its relatively short follow-up period compared to other major RP cohorts with long-term outcomes, which underpower our statistical analysis. Fifth, our study is limited by the relatively high rate of censoring events in the survival analysis. Because the censor rate is different from each group, there is some possibility for misleading from this statistical noise. Finally, we can observe relatively high upstaging and upgrading rates in our RP cohort, which can be another confounding factor. Further study is needed to validate our results.
Conclusion
The 8th edition of the AJCC stage group system has shown contradictory results, particularly between groups IIC and IIIA. We observed that the low-GS subgroup of IIIA showed significantly more favorable survival outcomes than the IIC and IIIA high-grade subgroups. Further study is needed to provide more accurate validation of the current 8th edition of AJCC stage groups.
Clinical Practice Points
The current prognosis group from AJCC guidelines showed some contradictory results, particularly between stage groups IIC and IIIA. We suggest that the GS should be weighed more than the PSA level in predicting patient prognosis. Our new stratification system showed better prognostic ability than the current system.
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